logo
SC & ST students under BASS stopped from attending classes: 25,000 affected as schools await govt dues; managements warn of imminent closure

SC & ST students under BASS stopped from attending classes: 25,000 affected as schools await govt dues; managements warn of imminent closure

Time of India24-06-2025
HYDERABAD: Despite the reopening of schools on June 12 for the new academic year, SC and ST students who were admitted to private schools under the Best Available School Scheme (BASS) are not attending classes, as the school managements have stopped them from coming to school due to unpaid fees.
Speaking at a press conference in the city on Sunday, members of the Best Available School Management Association in Telangana stated that they would only allow the 25,000 affected students from the 237 participating schools to resume classes once the govt has cleared the outstanding fees from the past two years.
"We have been waiting for over two years now, and some even longer. Now, most of the managements do not even have the money to cover the day-to-day running costs of the schools.
We are unable to survive. We have no option but to stop children from attending classes. At least this way, we can demonstrate the difficulties we are facing in running schools," said Y Shekar Rao, general secretary of the association. He said that he has pending dues of 3 crore from the govt.
Of the 237 schools implementing the BASS scheme, he stated that at least 200 are on the verge of closure as they were unable to pay building rent, loan interest and power bills and other expenses.
"Many of us did not even open schools due to a lack of funds to run residential schools. The moment we open, we have to provide for all the children's needs, including food. This is the first time we have not resumed classes on the first day of reopening," said M Linga Reddy, who has implemented the BASS scheme for 12 years and is waiting for dues of 4.17 crore from the govt.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dollar Tree (DLTR) Rose Following the Divestiture
Dollar Tree (DLTR) Rose Following the Divestiture

Yahoo

time4 minutes ago

  • Yahoo

Dollar Tree (DLTR) Rose Following the Divestiture

The London Company, an investment management company, released 'The London Company Mid Cap Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities saw a double-digit surge in the second quarter following a sharp decline in the first quarter. The mid-cap composite rose 5.7% (5.5% net) in the second quarter, falling short of the Russell Midcap Index's 8.5% increase. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, The London Company Mid Cap Strategy highlighted stocks such as Dollar Tree, Inc. (NASDAQ:DLTR). Dollar Tree, Inc. (NASDAQ:DLTR) is a discount retailer. The one-month return of Dollar Tree, Inc. (NASDAQ:DLTR) was 11.63%, and its shares gained 10.21% of their value over the last 52 weeks. On July 29, 2025, Dollar Tree, Inc. (NASDAQ:DLTR) closed at $114.99 per share, with a market capitalization of $23.998 billion. The London Company Mid Cap Strategy stated the following regarding Dollar Tree, Inc. (NASDAQ:DLTR) in its second quarter 2025 investor letter: "Dollar Tree, Inc. (NASDAQ:DLTR) – DLTR was a top performer after it reached an agreement in March to sell its underperforming Family Dollar business, a decade-long drag on growth and margins. This divestiture has driven a stock re-rating, reflecting a higher-quality company focused on value creation at the Dollar Tree banner. The recent elimination of the de minimis exemption has yielded positive sentiment towards retailers like DLTR. We remain attracted to its pricing flexibility and margin enhancement opportunity. A shopper browsing through a discount retailers merchandise aisle filled with a wide variety of items. Dollar Tree, Inc. (NASDAQ:DLTR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 67 hedge fund portfolios held Dollar Tree, Inc. (NASDAQ:DLTR) at the end of the first quarter, which was 64 in the previous quarter. While we acknowledge the potential of Dollar Tree, Inc. (NASDAQ:DLTR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Dollar Tree, Inc. (NASDAQ:DLTR) and shared the list of defensive stocks billionaires are buying amid US trade tariff uncertainty. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

Yahoo

time4 minutes ago

  • Yahoo

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025. The live and replayed webcast of the call will be available through the company's website at The replay of the call will be available for three months. About Ultragenyx Pharmaceutical is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Contact Ultragenyx InvestorsJoshua Higair@ MediaJess Rowlands media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Marvell Technology stock soars 10% on Microsoft AI chip prospects
Marvell Technology stock soars 10% on Microsoft AI chip prospects

Yahoo

time4 minutes ago

  • Yahoo

Marvell Technology stock soars 10% on Microsoft AI chip prospects

-- Marvell Technology (NASDAQ:MRVL) stock surged 10% Wednesday after Fubon Research analysts highlighted the company's potential significant revenue opportunity from Microsoft's (NASDAQ:MSFT) AI chip initiatives. According to Fubon Research, Microsoft has upgraded specifications for its Maia300 chip, which Marvell is developing, from 3nm with HBM3E to a more advanced 2nm with HBM4. While this has pushed the production timeline from the first quarter of 2026 to the fourth quarter, analysts believe the project represents a substantial opportunity for Marvell. The Maia300 chip is expected to begin production with 300,000-400,000 units in the fourth quarter of 2026, ramping up to 1.2-1.5 million units in 2027. With an estimated average selling price of $8,000 per chip, Fubon projects potential revenue of $2.4 billion in 2026 and $10-12 billion in 2027 from this project alone. Analysts noted that Microsoft appears to be placing "higher expectations on Maia300 by MRVL, rather than Maia200 which is its own solution." This shift comes as Microsoft reportedly faces challenges with its internal chip design capabilities, with Fubon indicating the tech giant is likely to "rely more on MRVL for the current generations." The research also highlighted that Microsoft has increased the planned volume for its Maia200 chip from 40,000-60,000 units to 150,000-200,000 units in 2026, compensating for the delayed Maia300 rollout. Fubon's report suggests Microsoft may be more generous in pricing than Amazon (NASDAQ:AMZN) Web Services, with Maia300's $8,000 ASP substantially higher than AWS Trainium 2's $1,500, despite both projects having similar turnkey margins of 55-60%. Related articles Marvell Technology stock soars 10% on Microsoft AI chip prospects Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store